Literature DB >> 20347306

The development of antisense oligonucleotide therapies for Duchenne muscular dystrophy: report on a TREAT-NMD workshop hosted by the European Medicines Agency (EMA), on September 25th 2009.

F Muntoni1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20347306     DOI： 10.1016/j.nmd.2010.03.005

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN： 0960-8966            Impact factor:   4.296


× No keyword cloud information.
  18 in total

1.  Validity, Reliability, and Sensitivity of a 3D Vision Sensor-based Upper Extremity Reachable Workspace Evaluation in Neuromuscular Diseases.

Authors:  Jay J Han; Gregorij Kurillo; R Ted Abresch; Alina Nicorici; Ruzena Bajcsy
Journal:  PLoS Curr       Date:  2013-12-12

2.  226th ENMC International Workshop:: Towards validated and qualified biomarkers for therapy development for Duchenne muscular dystrophy 20-22 January 2017, Heemskerk, The Netherlands.

Authors:  Annemieke Aartsma-Rus; Alessandra Ferlini; Elizabeth M McNally; Pietro Spitali; H Lee Sweeney
Journal:  Neuromuscul Disord       Date:  2017-10-26       Impact factor: 4.296

3.  Proceedings of the 2017 National Toxicology Program Satellite Symposium.

Authors:  Susan A Elmore; Famke Aeffner; Dinesh S Bangari; Torrie A Crabbs; Stacey Fossey; Shayne C Gad; Wanda M Haschek; Jessica S Hoane; Kyathanahalli Janardhan; Ramesh C Kovi; Gail Pearse; Lyn M Wancket; Erin M Quist
Journal:  Toxicol Pathol       Date:  2017-11-07       Impact factor: 1.902

4.  Antisense mediated exon skipping therapy for duchenne muscular dystrophy (DMD).

Authors:  Camilla Brolin; Takehiko Shiraishi
Journal:  Artif DNA PNA XNA       Date:  2011-01

Review 5.  Duchenne muscular dystrophy: current cell therapies.

Authors:  Dorota Sienkiewicz; Wojciech Kulak; Bożena Okurowska-Zawada; Grażyna Paszko-Patej; Katarzyna Kawnik
Journal:  Ther Adv Neurol Disord       Date:  2015-07       Impact factor: 6.570

6.  Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings.

Authors:  Kate Bushby; Edward Connor
Journal:  Clin Investig (Lond)       Date:  2011-09

7.  Reachable workspace in facioscapulohumeral muscular dystrophy (FSHD) by Kinect.

Authors:  Jay J Han; Gregorij Kurillo; Richard T Abresch; Evan de Bie; Alina Nicorici; Ruzena Bajcsy
Journal:  Muscle Nerve       Date:  2014-11-19       Impact factor: 3.217

Review 8.  Targeting RNA to treat neuromuscular disease.

Authors:  Francesco Muntoni; Matthew J A Wood
Journal:  Nat Rev Drug Discov       Date:  2011-08-01       Impact factor: 84.694

9.  204th ENMC International Workshop on Biomarkers in Duchenne Muscular Dystrophy 24-26 January 2014, Naarden, The Netherlands.

Authors:  Alessandra Ferlini; Kevin M Flanigan; Hanns Lochmuller; Francesco Muntoni; Peter A C 't Hoen; Elizabeth McNally
Journal:  Neuromuscul Disord       Date:  2014-09-11       Impact factor: 4.296

10.  Multiple exon skipping strategies to by-pass dystrophin mutations.

Authors:  Carl F Adkin; Penelope L Meloni; Susan Fletcher; Abbie M Adams; Francesco Muntoni; Brenda Wong; Steve D Wilton
Journal:  Neuromuscul Disord       Date:  2011-12-17       Impact factor: 4.296
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.